Deals Shaping the Medical Industry (05/2010)
Executive Summary
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Generics Bulletin Podcast – GenBioPro v. West Virginia: The Future Of Mifepristone In America, With Professor Greer Donley
Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.
EFSA's Lower Safe Intake Level For Selenium Stands Despite Supplement Industry’s Objections
The European Food Safety Authority has rejected a request from industry association Food Supplements Europe to apply its new lower intake limit for selenium to only selenomethionine and not other forms authorized for use in supplements.
Instead Of VC, Try Philanthropy: Inside Medical Research Charity LifeArc
In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.